VisionGate

9 articles about VisionGate

• VisionGate, Inc. Appoints R. John Glasspool as  Chief Operating and Strategy Officer and member of the Board of Directors

  10/11/2018

  VisionGate, Inc. is pleased to announce the appointment of R. John Glasspool as its Chief Operating and Strategy Officer. 

• VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy

  9/26/2018

  Breakthrough Research to be Presented at the 2018 World Conference on Lung Cancer

• Breakthrough Research to be Presented at the 2018 World Conference on Lung Cancer

  9/24/2018

  VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada.

• Making LIFE Better: VisionGate Receives AZBio Fast Lane Honors

  9/22/2015

• VisionGate's First Product, LuCED, Shows Promise For Screening Of Lung Cancer

  9/8/2015

• VisionGate Eyes IPO and Plans to Hire 200 New Employees

  7/16/2015

• VisionGate Release: Significant Lung Cancer Screening Study Published In The American Cancer Society Journal, Cancer Cytopathology

  7/7/2015

• New Study Shows High Sensitivity And Specificity For VisionGate's Luced® Test To Help Detect Lung Cancer Earlier

  5/15/2014

• VisionGate To Present Early Lung Cancer Detection Data At American Society of Clinical Oncology

  5/7/2014